Molecular-based approach for overcoming acquired resistance to EGFR tyrosine kinase inhibitors

• Project/Area Number: 21591011
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Single-year Grants
• Section: 一般
• Research Field: Respiratory organ internal medicine
• Research Institution: Kinki University
• Principal Investigator: OKAMOTO Isamu 近畿大学, 医学部, 准教授 (10411597)
• Co-Investigator(Kenkyū-buntansha): NAKAGAWA Kazuhiko 近畿大学, 医学部, 教授 (40298964) ; NISHIO Kazuto 近畿大学, 医学部, 教授 (10208134)
• Project Period (FY): 2009 – 2011
• Project Status: Completed (Fiscal Year 2011)
• Budget Amount: ¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000); Fiscal Year 2011: ¥780,000 (Direct Cost: ¥600,000、Indirect Cost: ¥180,000); Fiscal Year 2010: ¥780,000 (Direct Cost: ¥600,000、Indirect Cost: ¥180,000); Fiscal Year 2009: ¥2,730,000 (Direct Cost: ¥2,100,000、Indirect Cost: ¥630,000)
• Keywords: 非閉塞性肺疾患 / 肺線維症 / 呼吸器感染症 / 癌

Research Abstract

Most non-small cell lung cancer(NSCLC) tumors with activatingmutations of the EGFR are initially responsive to EGFR tyrosine kinase inhibitors(TKIs), but they subsequently develop resistance to these drugs. The effects of the second-generation, irreversible EGFR-TKI BIBW2992 and the TS-targeting agents S-1(or 5-fluorouracil) or pemetrexed synergistically inhibited the proliferation of NSCLC cells with the T790Mmutation in vitro. BIBW2992 induced down-regulation of TS in the gefitinib-resistant NSCLC cells, implicating depletion of TS in the enhanced antitumor effect of the combination therapy. The combination of BIBW2992 and either the oral fluoropyrimidine S-1 or pemetrexed also inhibited the growth of NSCLC xenografts with the T790Mmutation to an extent greater than that apparent with either agent alone. The addition of TS-targeting drugs to BIBW2992 is a promising strategy to overcome EGFR-TKI resistance inNSCLC with the T790Mmutation of EGFR.
Loss of PTEN(phosphatase and tensin homolog) was recently shown to contribute to resistance to EGFR-TKIs in EGFRmutation. positiveNSCLC through activation of the protein kinaseAKT. The combination therapywithYM155 and erlotinib inhibited the growth of tumors formed by EGFRmutation. positive, PTEN-deficientNSCLC cells in nudemice to a greater extent than did treatment with either drug alone. These results thus indicate that persistent activation of signaling by the AKT-survivin pathway induced by PTENloss underlies a mechanismof resistance to erlotinib-induced apoptosis in EGFRmutation. positiveNSCLC. They further suggest that the targeting of survivin has the potential to overcome EGFR-TKI resistance in EGFRmutation-positiveNSCLC.

Research Products

• [Journal Article] Combined effect of ALK and MEK inhibitor in EML4-ALK-positive non-small-cell lung cancer cells (2012)
  • Author(s): Tanizaki J, Okamoto I, Takezawa K, Sakai K, Azuma K, Kuwata K, Yamaguchi H, Hatashita E, Nishio K, Janne PA, Nakagawa K
  • Journal Title: British Journal of Cancer Volume: 106 Pages: 763-767
  • Peer Reviewed
• [Journal Article] Phase I clinical study of the angiogenesis inhibitor TSU-68 combined with carboplatin and paclitaxel in chemotherapy-naive patients with advanced non-small cell lung cancer (2012)
  • Author(s): Okamoto I, Yoshioka H, Takeda K, Satouchi M, Yamamoto N, Seto T, Kasahara K, Miyazaki M, Kitamura R, Ohyama A, Hokoda N, Nakayama H, Yoshihara E, Nakagawa K
  • Journal Title: Journal of Thoracic Oncology Volume: 7 Pages: 427-433
  • Peer Reviewed
• [Journal Article] Feasibility study of two schedules of sunitinib in combination with pemetrexed in patients with advanced solid tumors (2012)
  • Author(s): Okamoto I, Shimizu T, Miyazaki M, Tsurutani J, Ichikawa Y, Terashima M, Takeda M, Fumita S, Ohki E, Kimura N, Hashimoto J, Nakagawa K
  • Journal Title: Investigational New Drugs Volume: 30 Pages: 639-646
  • Peer Reviewed
• [Journal Article] Overcoming Erlotinib Resistance in EGFR Mutation-Positive Non-Small Cell Lung Cancer Cells by Targeting SurvivinMolecular (2012)
  • Author(s): Okamoto K, Okamoto I, Hatashita E, Kuwata K, Yamaguchi H, Kita A, Yamanaka K, Ono M, Nakagawa K
  • Journal Title: Cancer Therapeutics Volume: 11 Pages: 204-213
  • Peer Reviewed
• [Journal Article] Association of the expression of mutant EGFR protein as determined with mutation-specific antibodies in non-small cell lung cancer with progression-free survival after gefitinib treatment (2012)
  • Author(s): Azuma K, Okamoto I, Kawahara A, Taira T, Nakashima K, Hattori S, KinoshitaT, Takeda M, Nakagawa K, Takamori S, Kuwano M, Ono M, KageM
  • Journal Title: Journal of Thoracic Oncology Volume: 7 Pages: 122-127
  • Peer Reviewed
• [Journal Article] Phamacokinetics of docetaxel in a patient with non-small cell lung cancer undergoing continuous ambulatory peritoneal dialysis (2012)
  • Author(s): Kaneda H
  • Journal Title: Journal of Thoracic Oncology Volume: 7 Pages: 621-622
  • Peer Reviewed
• [Journal Article] Successful long-term treatment with pemetrexed of NSCLC associated with EML4-ALK and low thymidylate synthase expression (2012)
  • Author(s): Takeda M
  • Journal Title: Clinical Lung Cancer Volume: 13 Pages: 157-159
  • Peer Reviewed
• [Journal Article] Overcoming Erlotinib Resistance in EGFR Mutation-Positive Non-Small Cell Lung Cancer Cells by Targeting Survivin (2012)
  • Author(s): Okamoto K
  • Journal Title: Molecular Cancer Therapeutics Volume: 11 Pages: 204-213
  • Peer Reviewed
• [Journal Article] Roles of BIM induction and survivin down-regulation in lapatinib-induced apoptosis in breast cancer cells with HER2 amplification (2011)
  • Author(s): Tanizaki J, Okamoto I, Fumita S, Okamoto W, Nishio K, Nakagawa K
  • Journal Title: Oncogene Volume: 30 Pages: 4097-4106
  • Peer Reviewed
• [Journal Article] Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab (2011)
  • Author(s): Yonesaka K, Zejnullahu K, Okamoto I, Satoh T, Cappuzzo F, Souglakos J, Ercan D, Rogers A, Roncalli M, Takeda M, FujisakaY, Philips J, Shimizu T, Maenishi O, Cho Y, Sun J, Destro A, Taira K, Takeda K, OkabeT, Swanson J, Itoh H, Takada M, Lifshits E, Okuno K, Engelman A J, Shivdasani A R, Nishio K, Fukuoka M, Garcia V M, Nakagawa K, and Janne A. P
  • Journal Title: Science Translation Medicine Volume: 3
  • Peer Reviewed
• [Journal Article] MET Tyrosine Kinase Inhibitor Crizotinib(PF-02341066) Shows Differential Antitumor Effects in Non-small Cell Lung Cancer According to MET Alterations (2011)
  • Author(s): Tanizaki J, Okamoto I, Okamoto K, Takezawa K, Kuwata K, Yamaguchi H, Nakagawa K
  • Journal Title: Journal of Thoracic Oncology Volume: 10 Pages: 1624-1634
  • Peer Reviewed
• [Journal Article] Differential roles of trans-phosphorylated EGFR, HER2, HER3, and RET as heterodimerisation partners of MET in lung cancer with MET amplification (2011)
  • Author(s): Tanizaki J, Okamoto I, Sakai K, Nakagawa K
  • Journal Title: British Journal of Cancer Volume: 105 Pages: 807-813
  • Peer Reviewed
• [Journal Article] Single-agent gefitinib with concurrent radiotherapy for locally advanced non-small cell lung cancer harboring mutations of the epidermal growth factor receptor (2011)
  • Author(s): Okamoto I, Takahashi T, Okamoto H, Nakagawa K, Watanabe K, Nakamatsu K, Nishimura Y, Fukuoka M, Yamamoto N
  • Journal Title: Lung Cancer Volume: 72(1) Pages: 199-204
  • Peer Reviewed
• [Journal Article] Tymidylate synthase as a determinant of pemetrexed sensitivity in non-small cell lung cancer (2011)
  • Author(s): Takezawa K, Okamoto I, Okamoto W, Takeda M, Sakai K, Tsukioka S, Kuwata K, Yamaguchi H, Nishio K, Nakagawa K
  • Journal Title: British Journal of Cancer Volume: 104(10) Pages: 1594-601
  • Peer Reviewed
• [Journal Article] Role of ERK-BIM and STAT3-survivin signaling pathways in ALK inhibitor-induced apoptosis in EML4-ALK-positive lung cancer (2011)
  • Author(s): Takezawa K, Okamoto I, Nishio K, Janne P, Nakagawa K
  • Journal Title: Clinical Cancer Research Volume: 17(8) Pages: 2140-8
  • Peer Reviewed
• [Journal Article] Differential roles of STAT3 depending on the mechanism of STAT3 activation in gastric cancer cells (2011)
  • Author(s): Okamoto W, Okamoto I, Arao T, Yanagihara K, Nishio K, Nakagawa K
  • Journal Title: British Journal of Cancer Volume: 105(3) Pages: 407-12
  • Peer Reviewed
• [Journal Article] Thymidylate synthase and dihydropyrimidine dehydrogenase expression levels are associated with response to S-1 plus carboplatin in advanced non-small cell lung cancer (2011)
  • Author(s): Takeda M, Okamoto I, Hirabayashi N, Kitano M, Nakagawa K
  • Journal Title: Lung Cancer Volume: 73(1) Pages: 103-109
  • Peer Reviewed
• [Journal Article] MET Tyrosine Kinase Inhibitor Crizotinib (PF-02341066) Shows Differential Antitumor Effects in Non-small Cell Lung Cancer According (2011)
  • Author(s): Tanizaki J
  • Journal Title: Journal of Thoracic Oncology Volume: 10 Pages: 1624-1631
  • Peer Reviewed
• [Journal Article] Differential roles of trans-phosphorylated EGFR, HER2, HER3, and RET as heterodimerisation partners of MET in lung cancer with MET (2011)
  • Author(s): Tanizaki J
  • Journal Title: British Journal of Cancer Volume: 105 Pages: 807-813
  • Peer Reviewed
• [Journal Article] Single-agent gefitinib with concurrent radiotherapy for locally advanced non-small cell lung cancer harboring mutations of the epidermal growth (2011)
  • Author(s): Okamoto I
  • Journal Title: Lung Cancer Volume: 72(1) Pages: 199-204
  • Peer Reviewed
• [Journal Article] Tymidylate synthase as a determinant of pemetrexed sensitivity in non-small cell lung cancer (2011)
  • Author(s): Takezawa K
  • Journal Title: British Journal of Cancer Volume: 104(10) Pages: 1594-1601
  • Peer Reviewed
• [Journal Article] Role of ERK-BIM and STAT3-survivin signaling pathways in ALK inhibitor-induced apoptosis in EML4-ALK-positive lung cancer (2011)
  • Author(s): Takezawa K
  • Journal Title: Clinical Cancer Research Volume: 17(8) Pages: 2140-2148
  • Peer Reviewed
• [Journal Article] Differential roles of STAT3 depending on the mechanism of STAT3 activation in gastric cancer cells (2011)
  • Author(s): Okamoto W
  • Journal Title: British Journal of Cancer Volume: 105(3) Pages: 407-412
  • Peer Reviewed
• [Journal Article] Feasibility study of two schedules of sunitinib in combination with pemetrexed in patients with advanced solid tumors. (2011)
  • Author(s): Okamoto I
  • Journal Title: Investigational New Drugs. Volume: (in press)
  • Peer Reviewed
• [Journal Article] Switching addictions between HER2 and FGFR2 in HER2-positive breast tumor cells : FGFR2 as a potential target for salvage after lapatinib failure. (2011)
  • Author(s): Azuma K
  • Journal Title: Biochem Biophys Res Commun Volume: (in press)
  • Peer Reviewed
• [Journal Article] Role of ERK-BIM and STAT3-survivinsignaling pathways in ALK inhibitor-induced apoptosis in EML4-ALK-positive lung cancer. (2011)
  • Author(s): Takezawa K
  • Journal Title: Clinical Cancer Research Volume: (in press)
  • Peer Reviewed
• [Journal Article] Thymidylate synthase and dihydropyrimidine dehydrogenase expression levels are associated with response to S-1 plus carboplatin in advanced non-small cell lung cancer. (2011)
  • Author(s): Takeda M
  • Journal Title: Lung Cancer Volume: (in press)
  • Peer Reviewed
• [Journal Article] Perirenal hematoma associated with Bevacizumabnon-small cell lung cancer. (2011)
  • Author(s): Hayashi H
  • Journal Title: Investigational New Drugs Volume: (in press)
  • Peer Reviewed
• [Journal Article] High-dose dexamethasone plus antihistamine prevents colorectal cancer patients treated with modified FOLFOX6 from hypersensitivity reactions induced by oxaliplatin. (2011)
  • Author(s): Hayashi H
  • Journal Title: International Journal of Clinical Oncology Volume: (In press)
  • Peer Reviewed
• [Journal Article] Randomized, open-label, phase III, noninferiority trial comparing oral S-1 plus carboplatin with paclitaxel plus carboplatin in chemotherapy-naive patients with advanced non-small cell lung cancer : results of a West Japan Oncology Group(LETS) study (2010)
  • Author(s): Okamoto I, Yoshioka H, Morita S, Ando M, Takeda K, Seto T, Yamamoto N, Saka H, Asami K, Hirashima T, Kudoh S, Satouchi M, Ikeda N, Iwamoto Y, Sawa T, Miyazaki M, Tamura K, Kurata K, Fukuoka M, Nakagawa K
  • Journal Title: Journal of Clinical Oncology Volume: 28(36) Pages: 5240-5246
  • Peer Reviewed
• [Journal Article] Phase I Safety, Pharmacokinetic, and Biomarker Study of BIBF 1120, an Oral Triple Tyrosine Kinase Inhibitor in Patients with Advanced Solid Tumors (2010)
  • Author(s): Okamoto I, Kaneda H, Satoh T, Okamoto W, Miyazaki M, Morinaga R, Ueda S, Terashima M, Tsuya A, Sarashina A, Konishi K, Arao T, Nishio K, Kaiser R, Nakagawa K
  • Journal Title: Molecular Cancer Therapeutics Volume: 9(10) Pages: 2825-2833
  • Peer Reviewed
• [Journal Article] Does escalation study of pemetrexed in combination with carboplatin followed by pemetrexed maintenance therapy for advanced non-small cell lung cancer (2010)
  • Author(s): Okamoto I, Takeda K, Daga H, Miyazaki M, Yonesaka K, Kiyota H, Tsurutani J, Ueda S, Ichikawa Y, Takeda M, Sekiguchi R, Tominaga K, Enatsu S, Nambu Y, Nakagawa K
  • Journal Title: Lung Cancer Volume: 70(2) Pages: 168-173
  • Peer Reviewed
• [Journal Article] Phase I clinical and pharmacokinetic study of sorafenib in combination with carboplatin and paclitaxel in patients with advanced non-small cell lung cancer (2010)
  • Author(s): Okamoto I, Miyazaki M, Morinaga R, Kaneda H, Ueda S, Hasegawa Y, Satoh T, Kawada A, Fukuoka M, Fukino K, Tanigawa T, Nakagawa K
  • Journal Title: Investigational New Drugs Volume: 28(6) Pages: 844-853
  • Peer Reviewed
• [Journal Article] The emerging role of epidermal growth factor receptor(EGFR) inhibitors in first-line treatment for patients with advanced non-small cell lung cancer positive for EGFR mutations (2010)
  • Author(s): Okamoto I. Mitsudomi T, Nakagawa K, Fukuoka M
  • Journal Title: Therapeutic Advences in Medical Oncology Volume: 2(5) Pages: 301-307
  • Peer Reviewed
• [Journal Article] Epidermal growth factor receptor in relation to tumor development : EGFR-targeted anticancer therapy (2010)
  • Author(s): Okamoto I
  • Journal Title: FEBS Journal Volume: 277(2) Pages: 309-15
  • Peer Reviewed
• [Journal Article] Disturbance of the Growth Hormone-Insulin-like Growth Factor-1 Axis Associated with Poor Performance Status in Patients with Solid Tumors (2010)
  • Author(s): Okamoto I, Munakata M, Miyazaki M, Satoh T, Takahata T, Takamatsu Y, Muto O, Koike K, Ishitani K, Mukaiyama T, Sakata Y, Nakagawa K, Tamura K
  • Journal Title: Japanese Journal of Clinical Oncology Volume: 40(3) Pages: 222-226
  • Peer Reviewed
• [Journal Article] Phase I Clinical and Pharmacokinetic Study of RAD001(Everolimus) Administered Daily to Japanese Patients with Advanced Solid Tumors (2010)
  • Author(s): Okamoto I, Doi T, Ohtsu A, Miyazaki M, Tsuya A, Kurei K, Kobayashi K, Nakagawa K
  • Journal Title: Japanese Journal of Clinical Oncology Volume: 40(1) Pages: 17-23
  • Peer Reviewed
• [Journal Article] Role of survivin in EGFR inhibitor-induced apoptosis in non-small cell lung cancers positive for EGFR mutations (2010)
  • Author(s): Okamoto K, Okamoto I, Okamoto W, Tanaka K, Takezawa K, Kuwata K, Yamaguchi H, Nishio K, Nakagawa K
  • Journal Title: Cancer Research Volume: 70(24) Pages: 10402-10410
  • Peer Reviewed
• [Journal Article] TAK-701, a humanized monoclonal antibody to HGF, reverses gefitinib resistance induced by tumor-derived HGF in non-small cell lung cancer with an EGFR mutation (2010)
  • Author(s): Okamoto W, Okamoto I, Tanaka K, Hatashita E, Yamada Y, Kuwata K, Yamaguchi H, Arao T, Nishio K, Fukuoka M, Janne PA, Nakagawa K
  • Journal Title: Molecular Cancer Therapeutics Volume: 9(10) Pages: 2785-2792
  • Peer Reviewed
• [Journal Article] Successful treatment with erlotinib after gefitinib-induced severe interstitial lung disease (2010)
  • Author(s): Takeda M, Okamoto I, Makimura C, Fukuoka M, Nakagawa K
  • Journal Title: Journal of Thoracic Oncology Volume: 5(7) Pages: 1103-1104
  • Peer Reviewed
• [Journal Article] Identification of c-Src as a potential therapeutic target for gastric cancer and of MET activation as a cause of resistance to c-Src inhibition (2010)
  • Author(s): Okamoto W, Okamoto I, Yoshida T, Okamoto K, Takezawa K, Hatashita E, Yamada Y, Kuwata K, Arao T, Yanagihara K, Fukuoka M, Nishio K, Nakagawa K
  • Journal Title: Molecular Cancer Therapeutics Volume: 9(5) Pages: 1188-1197
  • Peer Reviewed
• [Journal Article] Synergistic antitumor effect of S-1 and HER2-targeting agents in gastric cancer with HER2 amplification (2010)
  • Author(s): Tanizaki J, Okamoto I, Takezawa K, Tsukioka S, Uchida J, Kiniwa M, Fukuoka M, Nakagawa K
  • Journal Title: Molecular Cancer Therapeutics Volume: 9(5) Pages: 1198-1207
  • Peer Reviewed
• [Journal Article] Enhanced anticancer effect of the combination of BIBW2992 and thymidylate synthase-targeted agents in non-small cell lung cancer with the T790M mutation of epidermal growth factor receptor (2010)
  • Author(s): Takezawa K, Okamoto I, Tanizaki J, Kuwata K, Yamaguchi H, Fukuoka M, Nishio K, Nakagawa K
  • Journal Title: Molecular Cancer Therapeutics Volume: 9(6) Pages: 1647-1656
  • Peer Reviewed
• [Journal Article] Identification of thymidylate synthase as a potential therapeutic target for lung cancer (2010)
  • Author(s): Takezawa K, Okamoto I, Tsukioka S, Uchida J, Kiniwa M, Fukuoka M, Nakagawa K
  • Journal Title: British Journal of Cancer Volume: 103(3) Pages: 354-361
  • Peer Reviewed
• [Journal Article] Marked anti-tumour activity of the combination of YM155, a novel survivin suppressant, and platinum-based drugs (2010)
  • Author(s): Iwasa T, Okamoto I, Takezawa K, Yamanaka K, Nakahara T, Kita A, Koutoku H, Sasamata M, Hatashita E, Yamada Y, Kuwata K, Fukuoka M, Nakagawa K
  • Journal Title: British Journal of Cancer Volume: 103(1) Pages: 36-42
  • Peer Reviewed
• [Journal Article] Rundomeed, on-label, phase 111, noninferiority, trial comparing oral 5-1 plus curboplatlin with pacllranet plow carhnplat fhewNmvapv-nelve unueuts pith advanced icon-small cell lung cancer : result of a Rust Japan Oncology GI-1 (WTS) study (2010)
  • Author(s): Okamoto I
  • Journal Title: Journal of Clinical Oncology Volume: 28(36) Pages: 5240-5246
  • Peer Reviewed
• [Journal Article] Phase I Safety, Pharmacokinetic, and Biomarker Study of BIBF 1120, an Ora Triple Tyrosine Kinase Inhibitor in Patients with Advanced Solid Tumors. (2010)
  • Author(s): Okamoto I
  • Journal Title: Molecular Cancer Therapeutics Volume: 9(10) Pages: 2825-2833
  • Peer Reviewed
• [Journal Article] Does escalation study of pemetrexed in combination with carboplatin followed by pemetrexed maintenance therapy for advanced non-small cell (2010)
  • Author(s): Okamoto I
  • Journal Title: Lung Cancer Volume: 70(2) Pages: 168-173
  • Peer Reviewed
• [Journal Article] Phase I clinical and pharmacokinetic study of sorafenib in combination with carhoplatin and paclitaxel in patients with advanced non-small cell lung cancer. (2010)
  • Author(s): Okamoto I
  • Journal Title: Investigational New Drugs Volume: 28(6) Pages: 844-853
  • Peer Reviewed
• [Journal Article] The emerging role of epidermal growth factor receptor (EGFR) inhibitors in first-line treatment for patients with advanced non-small cell lung cancer positive for (2010)
  • Author(s): Okamoto I
  • Journal Title: Therapeutic Advances in Medical Oncology Volume: 2(5) Pages: 301-307
  • Peer Reviewed
• [Journal Article] Epidermal growth factor receptor in relation to tumor development EGFR targeted anticancer therapy. (2010)
  • Author(s): Okamoto I
  • Journal Title: FEBS Journal Volume: 277(2) Pages: 309-315
  • Peer Reviewed
• [Journal Article] Disturbance of the Growth Hormone-Insulin-like Growth Factor-1 Axis Associated with Poor Performance Status in Patients with Solid Tumors. (2010)
  • Author(s): Okamoto I
  • Journal Title: Japanese Journal of Clinical Oncology Volume: 40(3) Pages: 222-226
  • Peer Reviewed
• [Journal Article] Phase I Clinical and Pharmacokinetic Study of RAD001 (Everolimus) Administered Daily to Japanese Patients with Advanced Solid Tumors. (2010)
  • Author(s): Okamoto I
  • Journal Title: Japanese Journal of Clinical Oncology Volume: 40(1) Pages: 17-23
  • Peer Reviewed
• [Journal Article] Role of survivin in EGFR inhibitor-induced apoptosis in non-small cell lung cancers positive for FGFR mutations. (2010)
  • Author(s): Okamoto K
  • Journal Title: Cancer Research Volume: 70(24) Pages: 10402-10410
  • Peer Reviewed
• [Journal Article] TAK-701, a humanized monoclonal antibody to HGF, reverses gefitinib resistance induced bytumor-derived HGF in non-small cell lung cancer with an EGFR mutation. (2010)
  • Author(s): Okamoto W
  • Journal Title: Molecular Cancer Therapeutics Volume: 9(10) Pages: 2785-2792
  • Peer Reviewed
• [Journal Article] Retreatment of recurrent malignant pleurall mesothelioma with cisplatin and Pemetrexed. (2010)
  • Author(s): Hayashi H
  • Journal Title: International Journal of Clinical Oncology Volume: 15(5) Pages: 497-499
  • Peer Reviewed
• [Journal Article] Successful treatment with erlotinib after gefitinib-related severe hepatotoxcity. (2010)
  • Author(s): Takeda M
  • Journal Title: Journal of Clinical Oncology Volume: 28(17)
  • Peer Reviewed
• [Journal Article] Successful treatment with erlotinib after gefitinib-induced severe interstitial lung disease. (2010)
  • Author(s): Takeda M
  • Journal Title: Journal of Thoracic Oncology Volume: 5(7) Pages: 1103-1104
  • Peer Reviewed
• [Journal Article] Identification of c-Src as a potential therapeutic target for gastric cancer and of MET activation as a cause of resistance to c-Src inhibition. (2010)
  • Author(s): Okamoto W
  • Journal Title: Molecular Cancer Therapeutics Volume: 9(5) Pages: 1188-1197
  • Peer Reviewed
• [Journal Article] Synergistic antitumor effect of S-1 and HER2-targeting agents in gastric cancer with HER2 amplification. (2010)
  • Author(s): Tanizaki J
  • Journal Title: Molecular Cancer Therapeutics Volume: 9(5) Pages: 1198-1207
  • Peer Reviewed
• [Journal Article] Enhanced anticancer effect of the combination of BIBW2992 and thymidylate synthase-targeted agents in non-small cell lung cancer with the T790M mutation of epidermal growth (2010)
  • Author(s): Takezawa K
  • Journal Title: Molecular Cancer Therapeutics Volume: 9(6) Pages: 1647-1656
  • Peer Reviewed
• [Journal Article] Identification of thymidylate synthase as a potential therapeutic target for lung cancer. (2010)
  • Author(s): Takezawa K
  • Journal Title: British Journal of Cancer Volume: 103(3) Pages: 354-361
  • Peer Reviewed
• [Journal Article] Marked anti-tumour activity of the combination of YM155, a novel surviving suppressant, and platinum-based drugs. (2010)
  • Author(s): Iwasa T
  • Journal Title: British Journal of Cancer Volume: 103 Pages: 36-42
  • Peer Reviewed
• [Journal Article] Cisplatin and Etoposide Chemotherapy Combined with Early Concurrent Twice daily Thoracic Radiotherapy for Limited-disease Small Cell Lung Cancer in (2010)
  • Author(s): Okamoto K
  • Journal Title: Japanese Journal of Clinical Oncology Volume: 40(1) Pages: 54-59
  • Peer Reviewed
• [Journal Article] Effects of Src inhibitors on cell growth and epidermal growth factor receptor and MET signaling in gefitinib-resistant non-small cell lung cancer cells with acquired MET (2010)
  • Author(s): Yoshida T
  • Journal Title: Cancer Science Volume: 101(1) Pages: 167-172
  • Peer Reviewed
• [Journal Article] Phase I clinical and pharmacokinetic study of the glucose-conjugated cytotoxic agent D : -19575 (glufosfamide) in patients with solid tumors. (2010)
  • Author(s): Shimizu T
  • Journal Title: Cancer Chemotherapy and Pharmacology Volume: 65 Pages: 243-250
  • Peer Reviewed
• [Journal Article] Gefitinib versus cisplatin plue docetaxel in patients with non-small-cell lung cancer Harbouring mutations of the epidermal growch factor receptor(WJTOG3405) : an open label, randcnised phase 3 trial. (2010)
  • Author(s): Mitsudomi T
  • Journal Title: Lancet Oncology Volume: 11(2) Pages: 121-128
  • Peer Reviewed
• [Journal Article] Epidermal growth factor receptor in relation to tumor development : EGFR-targeted anticancer therapy (2010)
  • Author(s): Okamoto I
  • Journal Title: FEBS Journal 277(2) Pages: 309-15
  • Peer Reviewed
• [Journal Article] S-1 : a new oral fluoropyrimidine in the treatment of patients with advanced non-small-cell lung cancer (2010)
  • Author(s): Okamoto I
  • Journal Title: Clinical Lung Cancer 10(4) Pages: 290-4
  • Peer Reviewed
• [Journal Article] Effects of Src inhibitors on cell growth and epidermal growth factor receptor and MET signaling in gefitinib-resistant non-small cell lung cancer cells with acquired MET plification (2010)
  • Author(s): Yoshida T
  • Journal Title: Cancer Science 101(1) Pages: 167-172
  • Peer Reviewed
• [Journal Article] Randomized Phase III Trial of Platinum-Doublet Chemotherapy Followed by Gefitinib Compared With Continued Platinum-Doublet Chemotherapy in Japanese Patients With Advanced Non-Small-Cell Lung Cancer : Results of a West Japan Thoracic Oncology Group Trial(WJTOG0203) (2010)
  • Author(s): Takeda K
  • Journal Title: Journal of Clinical Oncology 28(5) Pages: 753-760
  • Peer Reviewed
• [Journal Article] Phase I Clinical and Pharmacokinetic Study of RAD001(Everolimus)Administered Daily to Japanese Patients with Advanced Solid Tumors (2010)
  • Author(s): Okamoto I
  • Journal Title: Japanese Journal of Clinical Oncology 40(1) Pages: 17-23
  • Peer Reviewed
• [Journal Article] Phase II Trial of Amrubicin for Second-Line Treatment of Advanced Non-small Cell Lung Cancer : Results of the West Japan Thoracic Oncology Group Trial(WJTOG0401) (2010)
  • Author(s): Kaneda H
  • Journal Title: Journal of Thoracic Oncology 5(1) Pages: 105-9
  • Peer Reviewed
• [Journal Article] Cisplatin and Etoposide Chemotherapy Combined with Early Concurrent Twice-daily Thoracic Radiotherapy for Limited-disease Small Cell Lung Cancer in Elderly Patients (2010)
  • Author(s): Okamoto K
  • Journal Title: Japanese Journal of Clinical Oncology 40(1) Pages: 54-9
  • Peer Reviewed
• [Journal Article] Phase I clinical and pharmacokinetic study of the glucose-conjugated cytotoxic agent D : -19575(glufosfamide)in patients with solid tumors (2010)
  • Author(s): Shimizu T
  • Journal Title: Cancer Chemotherapy and Pharmacology 65 Pages: 243-250
  • Peer Reviewed
• [Journal Article] Inhibition of insulin-like growth factor 1 receptor by CP-751,871 radiosensitizes non-small cell lung cancer cells (2009)
  • Author(s): Iwasa T
  • Journal Title: Clinical Cancer Research 15(16) Pages: 5117-25
  • Peer Reviewed
• [Journal Article] Sorafenib inhibits non-small cell lung cancer cell growth by targeting B-RAF in KRAS wild-type cells and C-RAF in KRAS mutant cells (2009)
  • Author(s): Takezawa K
  • Journal Title: Cancer Research 69(16) Pages: 6515-21
  • Peer Reviewed
• [Journal Article] Combined survival analysis of prospective clinical trials of gefitinib for non-small cell lung cancer with EGFR mutations. Clinical Cancer Research (2009)
  • Author(s): Morita S
  • Journal Title: Clinical Cancer Research 15(13) Pages: 4493-8
  • Peer Reviewed
• [Journal Article] Addition of S-1 to the epidermal growth factor receptor inhibitor gefitinib overcomes gefitinib resistance in non-small cell lung cancer cell lines with MET amplification (2009)
  • Author(s): Okabe T
  • Journal Title: Clinical Cancer Research 15(3) Pages: 907-13
  • Peer Reviewed
• [Journal Article] Phase I study of YM155, a novel survivin suppressant, in patients with advanced solid tumors (2009)
  • Author(s): Satoh T
  • Journal Title: Clinical Cancer Research 15(11) Pages: 3872-80
  • Peer Reviewed
• [Journal Article] Phase I/II study of S-1 plus carboplatin in patients with advanced non-small cell lung cancer (2009)
  • Author(s): Tamura K
  • Journal Title: European Journal of Cancer 45(12) Pages: 2132-7
  • Peer Reviewed
• [Journal Article] Zoledronic acid-induced regression of multiple metastases at nonskeletal sites (2009)
  • Author(s): Okamoto K
  • Journal Title: Annals of Oncology 20(4) Pages: 796-7
  • Peer Reviewed
• [Journal Article] SRPX2 is overexpressed in gastric cancer and promotes cellular migration and adhesion (2009)
  • Author(s): Tanaka K
  • Journal Title: International Journal of Cancer 124(5) Pages: 1072-80
  • Peer Reviewed
• [Presentation] Emerging role of pemetrexed for first-line and maintenance chemotherapy for advanced nonsquamous NSCLC (2011)
  • Author(s): 岡本勇
  • Organizer: 第52回日本肺癌学会総会
  • Place of Presentation: 大阪国際会議場(大阪府)
  • Year and Date: 2011-11-03
• [Presentation] Molecular Based Patient Selection in Global Clinical Trials for Non-Small Cell Lung Cancer (2011)
  • Author(s): Okamoto I
  • Organizer: The European Multidisciplinary Cancer CongressESMO/JSMO Joint Symposium
  • Place of Presentation: ストックホルム(スウェーデン)
  • Year and Date: 2011-09-26
• [Presentation] Controversies in the Treatment for Advanced Cancer Controversies in the maintenance therapy for metastatic NSCLC (2011)
  • Author(s): Okamoto I
  • Organizer: 第9回日本臨床腫瘍学会学術集会ASCO/JSMO Joint Symposium
  • Place of Presentation: パシフィコ横浜(横浜市)
  • Year and Date: 2011-07-21
• [Presentation] 化学放射線療法の新展開放射線療法における分子標的治療薬の役割と展望 (2011)
  • Author(s): 岡本勇
  • Organizer: 第9回日本臨床腫瘍学会学術集会日本臨床腫瘍学会・日本放射線腫瘍学会合同シンポジウム
  • Place of Presentation: パシフィコ横浜(横浜市)
  • Year and Date: 2011-07-21
• [Presentation] 肺癌治療のControversy非小細胞肺癌治療におけるEGFRチロシンキナーゼ阻害剤(EGFR-TKIs)の諸問題 (2011)
  • Author(s): 岡本勇
  • Organizer: 第9回日本臨床腫瘍学会学術集会ワークショップ
  • Place of Presentation: パシフィコ横浜(横浜市)
  • Year and Date: 2011-07-21
• [Presentation] Controversies in the Treatment for Advanced Cancer Controversies in the maintenance therapy for metastatic NSCLC (2011)
  • Author(s): Okamoto I
  • Organizer: 第9回日本臨床腫瘍学会学術集会ASCO/JSMO Joint Symposium
  • Place of Presentation: パシフィコ横浜(神奈川県)
  • Year and Date: 2011-07-21
• [Presentation] 化学放射線療法の新展開放射線療法における分子標的治療薬の役割と展望 (2011)
  • Author(s): 岡本勇
  • Organizer: 第9回日本臨床腫瘍学会学術集会日本臨床腫瘍学会・日本放射線腫瘍学会合同シンポジウム
  • Place of Presentation: パシフィコ横浜(神奈川県)
  • Year and Date: 2011-07-21
• [Presentation] 肺癌治療のControversy非小細胞肺癌治療におけるEGFRチロシンキナーゼ阻害剤(EGFR-TKIs)の諸問題 (2011)
  • Author(s): 岡本勇
  • Organizer: 第9回日本臨床腫瘍学会学術集会ワークショップ
  • Place of Presentation: パシフィコ横浜(神奈川県)
  • Year and Date: 2011-07-21
• [Presentation] 化学療法総論II:分子標的薬剤の種類 (2011)
  • Author(s): 岡本勇
  • Organizer: 第9回日本臨床腫瘍学会第18回教育セミナーBセッション
  • Place of Presentation: パシフィコ横浜(神奈川県)
  • Year and Date: 2011-07-21
• [Presentation] Phase III trial comparing carboplatin/S-1 to carboplatin/paclitaxel in treatment-naive patients with advanced non-small cell lung cancer (NSCLC) : sugbroup analysis and updated results of the LETS study (2011)
  • Author(s): Satouchi M
  • Organizer: 14th World Conference on Lung Cancer
  • Place of Presentation: アムステルダム(オランダ)
  • Year and Date: 2011-07-05
• [Presentation] Phase III study comparing the effects of carboplatin plus S-1 and carboplatin plus paclitaxel in chemotherapy-naive patients with advanced non-small cell lung cancer : An updated report of the LETS study (WJTOG3605) (2011)
  • Author(s): Hirashima T
  • Organizer: 47th American Society of Clinical Oncology Annual Meeting
  • Place of Presentation: シカゴ(アメリカ)
  • Year and Date: 2011-06-06
• [Presentation] Survival results of a randomized, phase III trial of nab-paclitaxel and carboplatin compared with cremophor based paclitaxel and carboplatin as first-line therapy in advanced non-small cell lung cancer (2011)
  • Author(s): Socinski A.M.
  • Organizer: 47th American Society of Clinical Oncology Annual Meeting
  • Place of Presentation: シカゴ(アメリカ)
  • Year and Date: 2011-06-04
• [Presentation] A phase II trial of afatinib (BIBW 2992) in patients (pts) with advanced non-small cell lung cancer previously treated with erlotinib (E) or gefitinib (G) (2011)
  • Author(s): Yamamoto N
  • Organizer: 47th American Society of Clinical Oncology Annual Meeting
  • Place of Presentation: シカゴ(アメリカ)
  • Year and Date: 2011-06-03
• [Presentation] 非小細胞肺癌治療に対する放射線化学療法における分子標的治療薬の役割と展望 (2011)
  • Author(s): 岡本勇
  • Organizer: 第13回癌治療増感研究シンポジウム
  • Place of Presentation: 猿沢荘(奈良市)
  • Year and Date: 2011-02-12
• [Presentation] 非小細胞肺癌治療に対する放射線化学療法における分子標的治療薬の役割と展望 (2011)
  • Author(s): 岡本勇
  • Organizer: 第13回癌治療増感研究シンポジウム
  • Place of Presentation: 猿沢荘(奈良県)
  • Year and Date: 2011-02-12
• [Presentation] 抗がん薬耐性と臨床薬理最近の展開がん分子標的剤における耐性機構とその克服 (2010)
  • Author(s): 岡本勇
  • Organizer: 第31回日本臨床薬理学会総会
  • Place of Presentation: 国立京都国際会館(京都市)
  • Year and Date: 2010-12-01
• [Presentation] 抗がん薬耐性と臨床薬理 最近の展開がん分子標的剤における耐性機構とその克服 (2010)
  • Author(s): 岡本勇
  • Organizer: 第31回日本臨床薬理学会総会
  • Place of Presentation: 国立京都国際会館(京都府)
  • Year and Date: 2010-12-01
• [Presentation] 進行非小細胞肺癌治療における分子標的治療の実地導入 (2010)
  • Author(s): 岡本勇
  • Organizer: 第98回日本呼吸器学会東海地方学会
  • Place of Presentation: 三重県総合文化センター(津市)
  • Year and Date: 2010-11-13
• [Presentation] 進行非小細胞肺癌治療における分子標的治療の実地導入 (2010)
  • Author(s): 岡本勇
  • Organizer: 第98回日本呼吸器学会東海地方学会
  • Place of Presentation: 三重県総合文化センター(三重県)
  • Year and Date: 2010-11-13
• [Presentation] 肺癌の分子標的治療-基礎から臨床へ分子標的治療薬の作用機序から伺える今後の展開 (2010)
  • Author(s): 岡本勇
  • Organizer: 第51回日本肺癌学会総会
  • Place of Presentation: 広島国際会議場(広島市)
  • Year and Date: 2010-11-04
• [Presentation] 化学療法I非小細胞肺がん (2010)
  • Author(s): 岡本勇
  • Organizer: 第51回日本肺癌学会総会
  • Place of Presentation: 広島国際会議場(広島市)
  • Year and Date: 2010-11-04
• [Presentation] 非小細胞肺癌におけるTS-1の新たなエビデンス-Counterattack of 5-FU agents in NSCLC- (2010)
  • Author(s): 岡本勇
  • Organizer: 第51回日本肺癌学会総会
  • Place of Presentation: 広島国際会議場(広島市)
  • Year and Date: 2010-11-04
• [Presentation] 化学療法1 非小細胞肺がん (2010)
  • Author(s): 岡本勇
  • Organizer: 第51回日本肺癌学会総会
  • Place of Presentation: 広島国際会議場(広島県)
  • Year and Date: 2010-11-04
• [Presentation] 非小細胞肺癌におけるTS-1の新たなエビデンス-Counterattack of 5-FU agents in NSCLC- (2010)
  • Author(s): 岡本勇
  • Organizer: 第51回日本肺癌学会総会
  • Place of Presentation: 広島国際会議場(広島県)
  • Year and Date: 2010-11-04
• [Presentation] 肺癌の分子標的治療-基から臨床へ 分子標的治療薬の作用機序から伺える今後の展開 (2010)
  • Author(s): 岡本勇
  • Organizer: 第51回日本肺癌学会総会
  • Place of Presentation: 広島国際会議場(広島県)
  • Year and Date: 2010-11-04
• [Presentation] 肺癌の分子標的治療肺がん診療における血管新生阻害剤の現状と課題 (2010)
  • Author(s): 岡本勇
  • Organizer: 第48回日本癌治療学会総会
  • Place of Presentation: 国立京都国際会館(京都市)
  • Year and Date: 2010-10-30
• [Presentation] 肺癌の分子標的治療 肺がん診療における血管新生阻害剤の現状と課題 (2010)
  • Author(s): 岡本勇
  • Organizer: 第48回日本癌治療学会総会
  • Place of Presentation: 国立京都国際会(京都府)
  • Year and Date: 2010-10-30
• [Presentation] EGFR-TKI therapy for EGFR-mutated non-small cell lung cancer (2010)
  • Author(s): Okamoto I
  • Organizer: 第48回日本癌治療学会総会
  • Place of Presentation: 国立京都国際会館(京都市)
  • Year and Date: 2010-10-29
• [Presentation] EGFR-TKI therapy for EGFR-mutated non-small cell lung cancer (2010)
  • Author(s): Okamoto I
  • Organizer: 第48回日本癌治療学会総会
  • Place of Presentation: 国立京都国際会館(京都府)
  • Year and Date: 2010-10-29
• [Presentation] EGFR-TKI for EGFR mutated NSCLC : New evidence (2010)
  • Author(s): Okamoto I
  • Organizer: 35th European Society of Clinical Oncology
  • Place of Presentation: FIERA MILANO(イタリアミラノ)
  • Year and Date: 2010-10-09
• [Presentation] Emerging role of new oral agent S-1 in treatment of advanced NSCLC (2010)
  • Author(s): Okamoto I
  • Organizer: The 13th Chinese Society of Clinical
  • Place of Presentation: Jiuhua Resort and Convention Center(中国北京)
  • Year and Date: 2010-09-18
• [Presentation] 局所進行非小細胞肺癌に対する放射線化学療法に対する新展開～分子標的治療薬の役割～ (2010)
  • Author(s): 岡本勇
  • Organizer: 第92回日本肺癌学会関西支部会
  • Place of Presentation: 大阪国際会議場(大阪市)
  • Year and Date: 2010-07-10
• [Presentation] 局所進行非小細胞肺癌に対する射線化学療法に対する新展開～分子標的治療薬の役割～ (2010)
  • Author(s): 岡本勇
  • Organizer: 第92回日本肺癌学会関西支部会
  • Place of Presentation: 大阪国際会議場(大阪府)
  • Year and Date: 2010-07-10
• [Presentation] がん分子標的治療薬の耐性化メカニズム:基礎と臨床 (2010)
  • Author(s): 岡本勇
  • Organizer: 第14回日本がん分子標的治療学会総会
  • Place of Presentation: タワーホール船堀(東京江戸川区)
  • Year and Date: 2010-07-08
• [Presentation] がん分子標的治療薬の耐性化メカニズム:基礎と臨床 (2010)
  • Author(s): 岡本勇
  • Organizer: 第14回日本がん分子標的治療学会総会
  • Place of Presentation: タワーホール船堀(東京)
  • Year and Date: 2010-07-08
• [Presentation] Lung Cancer : ASC02010 topics (2010)
  • Author(s): Okamoto I
  • Organizer: Best of ASCO in Japan
  • Place of Presentation: 東京ビッグサイト国際会議場(東京)
  • Year and Date: 2010-07-03
• [Presentation] 進行非小細胞肺癌の化学療法における病理診断の重要性 (2010)
  • Author(s): 岡本勇
  • Organizer: 第99回日本病理学会総会
  • Place of Presentation: 京王プラザホテル(東京都新宿区)
  • Year and Date: 2010-04-27
• [Presentation] 進行非小細胞肺癌の化学療法における病理診断の重要性 (2010)
  • Author(s): 岡本勇
  • Organizer: 第99回日本病理学会総会
  • Place of Presentation: 京王プラザホテル(東京)
  • Year and Date: 2010-04-27
• [Presentation] Chemo-radiation for locally advanced NSCLC Integration of EGFR-targeted agents (2010)
  • Author(s): Okamoto I
  • Organizer: 9th International Conference of the Asian Clinical Oncology Society(ACOS)
  • Place of Presentation: 岐阜グランドホテル(岐阜市)
• [Presentation] Chemo-radiation for locally advanced NSCLC Integration of EGFR-targeted agents (2010)
  • Author(s): Okamoto I
  • Organizer: 9th International Conference of the Asian Clinical Oncology Society (ACOS)
  • Place of Presentation: 岐阜グランドホテル(岐阜県)
• [Presentation] EGFR-TKI in non-small cell lung cancer ～WJOG trial～ (2009)
  • Author(s): 岡本勇
  • Organizer: WJOG 3rd International Symposium on Clinical Trial
  • Place of Presentation: 大阪国際会議場(大阪府)
  • Year and Date: 2009-11-27
• [Presentation] パネルデイスカッション;非小細胞肺癌の組織型と治療戦略化学療法(分子標的治療を含む) (2009)
  • Author(s): 岡本勇
  • Organizer: 第50回日本肺癌学会総会
  • Place of Presentation: 京王プラザホテル(東京都新宿区)
  • Year and Date: 2009-11-13
• [Presentation] パネルデイスカッション;非小細胞肺癌の組織型と治療戦略 化学療法(分子標的治療を含む) (2009)
  • Author(s): 岡本勇
  • Organizer: 第50回日本肺癌学会総会
  • Place of Presentation: 京王プラザホテル(東京都)
  • Year and Date: 2009-11-13
• [Presentation] シンポジウム;分子標的治療の基礎と臨床EGFR遺伝子検査とEGFR-TKI治療の実践 (2009)
  • Author(s): 岡本勇
  • Organizer: 第50回日本肺癌学会総会
  • Place of Presentation: 京王プラザホテル(東京都新宿区)
  • Year and Date: 2009-11-12
• [Presentation] シンポジウム;分子標的治療の基礎と臨床 EGFR遺伝子検査とEGFR-TKI治療の実践 (2009)
  • Author(s): 岡本勇
  • Organizer: 第50回日本肺癌学会総会
  • Place of Presentation: 京王プラザホテル(東京都)
  • Year and Date: 2009-11-12
• [Presentation] Molecular-based treatment strategy in EGFR-targeted therapies (2009)
  • Author(s): Isamu Okamoto
  • Organizer: The 19th HCS-The 3rd Three Universities' Consortium International Symposium
  • Place of Presentation: 広島国際会議場(広島市)
  • Year and Date: 2009-11-01
• [Presentation] Molecular-based treatment strategy in EGFR-targeted therapies (2009)
  • Author(s): 岡本勇
  • Organizer: The 19th HCS-The 3rd Three Universities' Consortium International Symposium
  • Place of Presentation: 広島国際会議場(広島県)
  • Year and Date: 2009-11-01
• [Presentation] MET遺伝子増幅を伴うゲフィチニブ獲得耐性非小細胞肺癌におけるSrc阻害剤の効果 (2009)
  • Author(s): 岡本勇
  • Organizer: 第68回日本癌学会学術総会
  • Place of Presentation: パシフィコヨコハマ(横浜市)
  • Year and Date: 2009-10-02
• [Presentation] MET遺伝子増幅を伴うゲフィチニプ獲得耐性 非小細胞肺癌におけるSrc阻害剤の効果 (2009)
  • Author(s): 岡本勇
  • Organizer: 第68回日本癌学会学術総会
  • Place of Presentation: パシフィコヨコハマ(神奈川県)
  • Year and Date: 2009-10-02
• [Presentation] Phase I Clinical and Biomarker Study of BIBF1120 (2009)
  • Author(s): Isamu Okamoto
  • Organizer: 45th Annual Meeting of the American Society of Clinical Oncology
  • Place of Presentation: County Convention Center(アメリカフロリダ州)
  • Year and Date: 2009-05-30
• [Presentation] Phase I Clinical and Biomarker Study of BIBF1120 (2009)
  • Author(s): 岡本勇
  • Organizer: 45th Annual Meeting of the American Society of Clinical Oncology
  • Place of Presentation: Orange County Convention Center(アメリカ フロリダ州)
  • Year and Date: 2009-05-30